NOXXON PHARMA ANNOUNCES COLLABORATION WITH NATIONAL CENTER FOR TUMOR DISEASES IN HEIDELBERG FOR NOX-A12/KEYTRUDA® PHASE 1/2 COMBINATION TRIAL

LEADING CANCER CENTER TO CONDUCT NOXXON TRIAL IN METASTATIC COLORECTAL AND PANCREAS CANCER PATIENTS
TRIAL IS PART OF COLLABORATION WITH MERCK & CO/MSD

Berlin, Germany, May 16, 2017 - NOXXON Pharma N.V. (Alternext Paris: ALNOX), a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, today announced the signing of an agreement with the National Center for Tumor Diseases (NCT) in Heidelberg under which the NCT will conduct a trial evaluating NOXXON's lead product candidate NOX-A12 in combination with Keytruda® (pembrolizumab) in metastatic pancreatic and colorectal cancer. In some preclinical studies, NOX-A12 has shown an ability to make the immediate area surrounding a model tumor, the so-called tumor microenvironment, more accessible to the immune system. The ability of many tumors to use the tumor microenvironment to hide from the immune system is believed to contribute to the insensitivity of some tumors towards checkpoint inhibitors, such as Keytruda®.

The NCT is a leading center for cancer research and treatment, located in Heidelberg, Germany. It was jointly founded by the German Cancer Research Center (DKFZ), Heidelberg University Hospital, Medical Faculty Heidelberg and German Cancer Aid (Deutsche Krebshilfe) in 2004 to conduct interdisciplinary research for preventing and treating cancer to ultimately benefit patients.

The NCT investigators leading the clinical trial include Prof. Dr. Dirk Jäger, Managing Director, head of the clinical and tumor immunology research groups, and Dr. Niels Halama, Group Leader, both recognized leaders in clinical cancer research with significant experience in studying the tumor microenvironment in a clinical setting. Throughout his career, Prof. Dr. Jäger has focused on tumor and immunology as well as the interdisciplinary connections between both fields, both scientifically and clinically.

NOXXON's Chief Medical Officer, Dr. Jarl Ulf Jungnelius, commented: “Dr. Jäger and Dr. Halama are experts in the treatment of metastatic cancer patients as well as the tumor microenvironment. We are extremely pleased that they will be collaborating with NOXXON on this groundbreaking study.”

Prof. Dr. Jäger, Managing Director of the NCT Heidelberg, commented: “This trial will enable us to explore the potential of NOX-A12 in combination with Keytruda® to benefit patients with few viable treatment options. Importantly, the trial will help us to better understand the ability of NOX-A12 to modify the tumor microenvironment and make it more accessible to the immune system to facilitate tumor destruction.”
About NOXXON

NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON’s goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy). NOXXON’s Spiegelmer® platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12, which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with Keytruda® (pembrolizumab) in pancreatic and colorectal cancer. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, The Netherlands and its office in Berlin, Germany. Further information can be found at: www.noxxon.com

About the National Center for Tumor Diseases (NCT) Heidelberg

The NCT Heidelberg is a joint institution of the German Cancer Research Center, Heidelberg University Hospital and German Cancer Aid. The NCT’s goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.